Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 19;9(5):56.
doi: 10.3390/ncrna9050056.

Long Non-Coding RNA TUG1 Gene Polymorphism and TUG1 Expression Level as Molecular Biomarkers of Systemic Lupus Erythematosus and Lupus Nephritis

Gehan Abd-Elfatah Tawfeek  1 , Heba Kasem  2 , Eman Ali Abdallah  3   4 , Mohammed Almulhim  4 , Abdullah Almulhim  5 , Mohammed Albarqi  5 , Khaled Mohamed Amin Elzorkany  2   4
Affiliations

Long Non-Coding RNA TUG1 Gene Polymorphism and TUG1 Expression Level as Molecular Biomarkers of Systemic Lupus Erythematosus and Lupus Nephritis

Gehan Abd-Elfatah Tawfeek et al. Noncoding RNA. .

Abstract

Long non-coding RNA (lncRNA) TUG1 acts as a proto-oncogene, allowing the proliferation of tumor cells, and it has been related to inflammation. Therefore, we aimed in this study to investigate for the first time the role of TUG1 gene polymorphism and the TUG1 level as biomarkers in systemic lupus erythematosus (SLE) and their link to lupus nephritis 145 SLE. A total of 145 healthy controls were subjected to clinical and laboratory evaluation. The disease activity was assessed by the SLE disease activity index (SLEDAI) score. SLE patients were divided into two subgroups according to the presence of lupus nephritis. The TUG1 gene polymorphisms rs5749201 and rs886471 were determined by Sanger sequencing, and TUG1 expression was assessed by qRT-PCR. There was a significant increase in the risk of SLE AA, TA, dominant genotypes, and the A allele of rs5749201 (p < 0.001) by 4.9-, 10.1-, 6.5-, and 2.5-fold in comparison to the relative control. GG and TG, dominant genotypes and the G allele of rs886471 (p < 0.01) increased the risk by 5.09-, 11.9-, 6.5-, and 2.6-fold. AA, A allele, dominant and recessive rs5749201genotypes increased the risk of lupus nephritis by 16.6-, 7.4-, 7.1-, and 12.2-fold, respectively (p < 0.05). GG, dominant and recessive genotypes, and the G allele of rs886471 increased the risk of lupus nephritis by 17.04-, 7.8-, 9.4-, and 6.08-fold, respectively (p < 0.05). Additionally, the AG haplotype increased the risk of SLE and lupus nephritis by 2.7- and 7.8-fold, respectively. The AA rs5749201 and GG rs886471 variants are significantly associated with more severe disease (p < 0.001). TUG1 expression was significantly higher in SLE than in the control and in the lupus nephritis than in non-lupus nephritis cases (p < 0.05). Interestingly, AA rs5749201 and GG rs886471 were significantly associated with higher TUG1 levels (p < 0.001). It was also found that AA rs5749201 and high SLEDAI were predictors of lupus nephritis. Overall, our findings illustrated for the first time that TUG1 gene rs5749201 and rs886471 variants were associated with increased risk of SLE, more severe disease, and lupus nephritis, and the TUG1 level could be used as a diagnostic biomarker of SLE and lupus nephritis.

Keywords: TUG1 expression; lncRNA TUG1 SNPs; lupus nephritis; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
LncRNA TUG1 expression in cases and control by qRT-PCR. Ct values were processed using 2−ΔΔCT method, and TUG1 expression was normalized to U6 endogenous control. Post-amplification melting-curve analysis ensured reaction specificity.
Figure 2
Figure 2
LncRNA TUG1 expression level in the studied groups. (A): TUG1 level between SLE cases and healthy control, (B): TUG1 level between LN and non-LN. *: Statistically significant at p ≤ 0.05.
Figure 3
Figure 3
Relation of TUG 1 gene polymorphism and TUG 1 level. *: Statistically significant at p ≤ 0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Izmirly P.M., Wan I., Sahl S., Buyon J.P., Belmont H.M., Salmon J.E., Askanase A., Bathon J.M., Geraldino-Pardilla L., Ali Y., et al. The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis Rheumatol. 2017;69:2006–2017. doi: 10.1002/art.40192. - DOI - PMC - PubMed
    1. Barber M.R.W., Drenkard C., Falasinnu T., Hoi A., Mak A., Kow N.Y., Svenungsson E., Peterson J., Clarke A.E., Ramsey-Goldman R. Global epidemiology of systemic lupus erythematosus. Nat. Rev. Rheumatol. 2021;17:515–532. doi: 10.1038/s41584-021-00668-1. - DOI - PMC - PubMed
    1. Tsokos G.C., Lo M.S., Costa Reis P., Sullivan K.E. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 2016;12:716–730. doi: 10.1038/nrrheum.2016.186. - DOI - PubMed
    1. Pan L., Lu M.P., Wang J.H., Xu M., Yang S.R. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J. Pediatr. 2020;16:19–30. doi: 10.1007/s12519-019-00229-3. - DOI - PMC - PubMed
    1. Taheri M., Eghtedarian R., Dinger M.E., Ghafouri-Fard S. Exploring the Role of Non-Coding RNAs in the Pathophysiology of Systemic Lupus Erythematosus. Biomolecules. 2020;10:937. doi: 10.3390/biom10060937. - DOI - PMC - PubMed

LinkOut - more resources